Compare EBF & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBF | CTNM |
|---|---|---|
| Founded | 1909 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.9M | 550.7M |
| IPO Year | 1994 | 2024 |
| Metric | EBF | CTNM |
|---|---|---|
| Price | $22.62 | $8.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $22.14 |
| AVG Volume (30 Days) | 144.1K | ★ 1.3M |
| Earning Date | 09-21-2026 | 11-02-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ 7.79 | 0.46 |
| EPS | ★ 0.76 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.01 | N/A |
| Revenue Next Year | $0.92 | N/A |
| P/E Ratio | $30.11 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.30 | $6.73 |
| 52 Week High | $23.09 | $17.79 |
| Indicator | EBF | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 58.09 | 33.47 |
| Support Level | $19.92 | N/A |
| Resistance Level | $22.91 | $13.72 |
| Average True Range (ATR) | 0.37 | 0.99 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 56.36 | 21.74 |
Ennis Inc is a trade printer company that manufactures a broad range of printed products throughout the United States. It is engaged in the business of manufacturing, designing, and selling business forms and other printed business products to distributors located in the United States. Through a network of independent distributors, its channel encompasses independent print distributors, commercial printers, direct mail, fulfillment companies, payroll and accounts payable software companies, and advertising agencies, among others. The group operates in a single reportable segment called Print and derives its operating revenues from the manufacturing of mostly custom or semi-custom printed products sold mostly to independent distributors in the United States.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.